angiogenesis inhibitor

(redirected from Angiogenesis inhibitors)
Also found in: Dictionary, Medical.
  • noun

Words related to angiogenesis inhibitor

a drug that is designed to prevent the growth of blood vessels that nourish tumors

References in periodicals archive ?
This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following Product Segments: Angiogenesis Inhibitors, and Angiogenesis Stimulators.
But new research suggests certain angiogenesis inhibitors may actually promote the growth of tumours.
PI-88 is a compound that is unique among other angiogenesis inhibitors, and we are looking forward to investigating its potential in treating cancer patients," Dr.
Her paper, "Angiogenesis Inhibitors Endostatin or TNP-470 Reduce Intimal Neovascularization and Plaque Growth in Apolipoprotein e-Deficient Mice," showed that the growth of the small blood vessel network feeding coronary artery plaques in mice could be reduced by giving them an angiogenesis inhibitor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, depending on the tumor type, approximately one-quarter to one-third of surveyed Brazilian and Mexican oncologists' patients who are eligible for treatment with angiogenesis inhibitors do not receive such therapy, primarily because of reimbursement and/or budget-related factors.
Table 24: US Historic Review for Angiogenesis Inhibitors &
Rupnick and her colleagues have ruled out the possibility that angiogenesis inhibitors simply made the mice sick or spoiled their taste for food.
In 2009, angiogenesis inhibitors captured more than three-quarters of the renal cell carcinoma drug market, with Pfizer's Sutent accounting for 61 percent of sales in this class," said Decision Resources Analyst Karen Pomeranz, Ph.
Folkman's lab has developed angiogenesis inhibitors that are now in clinical trials.
The prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations, we identify that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer.
Angiogenesis stimulants last only a short time, whereas the angiogenesis inhibitors seem to work for months, at least in mice.
Because angiogenesis inhibitors have the potential to treat multiple types of cancers with little systemic toxicity, their commercial impact may be vast there since cancer markets historically have tolerated high-price agents.
Several new agents in development seek to achieve this goal, including immune system modulators (such as MAbs and immunotoxins), cell-cycle inhibitors, proteasome inhibitors, apoptosis inducers, and angiogenesis inhibitors.